Today: 4 March 2026
Subscribe

Khadija Saeed

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

Gevo Inc (GEVO) Stock: Q3 2025 Earnings Beat, DOE Loan Extension and 2026 Price Forecasts Explained

Gevo Inc (GEVO) Stock: Q3 2025 Earnings Beat, DOE Loan Extension and 2026 Price Forecasts Explained

Gevo Inc. (NASDAQ: GEVO) reported Q3 2025 revenue of $42.7 million, up sharply from $2 million a year earlier, and posted positive adjusted EBITDA. The company’s shares trade near $2.29, with a market cap around $550 million. Gevo has secured an extended DOE loan for its sustainable aviation fuel project and is monetizing federal clean fuel tax credits.
7 December 2025
··
Invesco NASDAQ 100 ETF (QQQM): Latest News, Price Action and 2026–2030 Forecasts as of December 7, 2025

Invesco NASDAQ 100 ETF (QQQM): Latest News, Price Action and 2026–2030 Forecasts as of December 7, 2025

The Invesco NASDAQ 100 ETF (QQQM) closed near $257.53 on December 7, 2025, just below record highs, amid strong inflows and renewed interest in mega-cap tech stocks. Analysts and AI models now forecast 2026–2030 returns ranging from single-digit gains to several hundred percent upside. QQQM has returned about 120% over five years, outpacing the S&P 500. The fund’s top holdings include Nvidia, Apple, Microsoft, Broadcom, and Amazon.
7 December 2025
·······
Intuitive Surgical (ISRG) Stock on December 7, 2025: Earnings Beat, Da Vinci 5 Momentum and What Wall Street Expects Next

Intuitive Surgical (ISRG) Stock on December 7, 2025: Earnings Beat, Da Vinci 5 Momentum and What Wall Street Expects Next

Intuitive Surgical shares closed at $575.34 on December 5, up 1.18%, near the top of their 52-week range. CalPERS raised its stake by 7% in Q2, while Executive Chair Gary Guthart sold $13 million in stock on December 1. Trading volume was light, but ISRG outperformed medtech peers. Some analysts describe the stock’s technical outlook as neutral.
7 December 2025
·
Northrop Grumman (NOC) Stock: Latest News, Price Targets and Investment Outlook as of December 7, 2025

Northrop Grumman (NOC) Stock: Latest News, Price Targets and Investment Outlook as of December 7, 2025

Northrop Grumman closed at $548.97 on December 5, down 0.7% for the day but up about 15% over the past year. Technical models from Intellectia and StockTradersDaily flag weak near-term sentiment and downside risk, despite solid long-term fundamentals. Recent earnings showed EPS of $7.67 and 4.3% revenue growth year-over-year. The company declared a quarterly dividend of $2.31 per share in November.
7 December 2025
··
Wayfair (W) Stock: 2025 Rally, Jefferies Downgrade and New Wall Street Forecasts – Latest News as of December 7, 2025

Wayfair (W) Stock: 2025 Rally, Jefferies Downgrade and New Wall Street Forecasts – Latest News as of December 7, 2025

Wayfair shares closed at $95.21 on December 5, 2025, up over 140% year-to-date, with a market cap near $12.3 billion. Jefferies downgraded the stock to “Hold” this week, citing weak holiday demand and stretched valuation, sending shares down 5.7% intraday. Insider selling has increased, but most analysts still rate the stock a “Moderate Buy.” Consensus price target stands at $105.29.
7 December 2025
·
Ondas Holdings (ONDS) Stock: Earnings Breakout, Drone Mega-Deals and 2026 Forecast Explained

Ondas Holdings (ONDS) Stock: Earnings Breakout, Drone Mega-Deals and 2026 Forecast Explained

Ondas Holdings (NASDAQ: ONDS) closed at $9.07 on December 5, 2025, with a market cap near $3.4 billion after a yearlong rally of over 1,000%. Q3 2025 revenue jumped to $10.1 million, up more than sixfold year-over-year, but the company posted a net loss with EPS at –$0.06. Trading volume surged to 82 million shares, while guidance for 2026 revenue was raised to at least $110 million.
7 December 2025
··
YieldMax Ultra Option Income Strategy ETF (ULTY) Stock: 2025 Price, 77% Yield, Reverse Split and 2026 Outlook

YieldMax Ultra Option Income Strategy ETF (ULTY) Stock: 2025 Price, 77% Yield, Reverse Split and 2026 Outlook

YieldMax Ultra Option Income Strategy ETF (ULTY) closed at $39.98 on December 5, 2025, following a 1-for-10 reverse split and a year-to-date price drop of about 60%. The fund’s official distribution rate stands at 76.99%, with some data showing a trailing 12-month yield above 120%. Assets under management are near $1.4 billion. ULTY charges a 1.30% expense ratio and holds about 80–100 positions.
7 December 2025
··
Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb shares closed at $52.15 on December 5, 2025, after a week marked by a surprise Alzheimer’s drug trial update, major hematology data, and a legal setback. The stock rebounded 7% over several days, adding $7 billion in market value. BMY trades at a trailing P/E of 17.5x with a 4.7–5% dividend yield. Analyst consensus rates the stock a hold, with modest upside expected.
7 December 2025
·
Air Transat Pilots Issue 72‑Hour Strike Notice: Flight Suspensions, Timeline and Passenger Rights Explained

Air Transat Pilots Issue 72‑Hour Strike Notice: Flight Suspensions, Timeline and Passenger Rights Explained

Air Transat will begin suspending flights on December 8 after its pilots issued a 72-hour strike notice, setting up a possible walkout on December 10. The airline says all flights will be halted by December 9 and is working to return passengers and crews to their points of origin. The notice affects about 700 pilots represented by ALPA. Talks continue as the union threatens to strike Wednesday morning.
7 December 2025
JetBlue Airways (JBLU) Stock: December 7, 2025 News, Forecasts and Analysis

JetBlue Airways (JBLU) Stock: December 7, 2025 News, Forecasts and Analysis

JetBlue shares closed at $4.79 on December 5, up 3% for the day but down 40% from the January high. The airline reported a Q3 loss of $0.40 per share, slightly better than expected, and revenue of $2.32 billion, down 1.8% year-over-year. Management continues to cut routes and defer aircraft spending under its JetForward plan. The stock remains deeply discounted amid ongoing losses and operational setbacks.
7 December 2025
·
MongoDB (MDB) Stock Outlook: Q3 Earnings Shock, New CEO, AI Push and Wall Street Forecasts as of December 7, 2025

MongoDB (MDB) Stock Outlook: Q3 Earnings Shock, New CEO, AI Push and Wall Street Forecasts as of December 7, 2025

MongoDB shares closed near $410, just below their 52-week high, after reporting Q3 FY2026 revenue of $628.3 million, up 19% year-over-year and above estimates. Atlas cloud revenue jumped 30% and now makes up about 75% of total sales. Non-GAAP EPS reached $1.32, beating forecasts. The company added 2,600 customers in the quarter, totaling over 62,500.
7 December 2025
···
Micron Technology (MU) Stock on December 7, 2025: AI Memory Supercycle, Crucial Exit, and Fresh Wall Street Forecasts

Micron Technology (MU) Stock on December 7, 2025: AI Memory Supercycle, Crucial Exit, and Fresh Wall Street Forecasts

Micron shares closed at $237.22 on December 5, up 4.7% after an analyst upgrade. The stock has surged over 170% in 2025, fueled by AI demand and a shift to high-bandwidth memory. On December 3, Micron said it will exit its Crucial consumer memory business by February 2026 to focus on AI data centers. Analysts remain positive as volumes and price targets climb.
7 December 2025
··
Blackstone Inc (BX) Stock on December 7, 2025: Latest News, Analyst Forecasts and Outlook

Blackstone Inc (BX) Stock on December 7, 2025: Latest News, Analyst Forecasts and Outlook

Blackstone closed a $130 million deal for San Francisco’s Four Seasons Hotel and launched a new retirement savings unit as regulators increase scrutiny of private markets. Shares ended December 5 at $152.15, over 20% below the 52-week high but up more than 100% over three years. Analysts estimate fair value at $179.78, citing optimism about earnings and capital deployment.
7 December 2025
·
Newmont Corporation (NEM) Stock Outlook: Analyst Upgrades, Gold Supercycle and 2026 Forecasts as of December 7, 2025

Newmont Corporation (NEM) Stock Outlook: Analyst Upgrades, Gold Supercycle and 2026 Forecasts as of December 7, 2025

Newmont shares closed near $90, up about 140% year to date, as gold prices hit records above $4,300 an ounce and the company reported surging free cash flow after the Newcrest acquisition. Market cap stands just under $99 billion. Most brokerages rate NEM a “Buy,” though some warn the stock may have outpaced fundamentals. Institutional ownership is estimated at 69–80%.
7 December 2025
Honeywell International Inc (HON) Stock Today: Latest News, 2026 Outlook and Analyst Forecasts – December 7, 2025

Honeywell International Inc (HON) Stock Today: Latest News, 2026 Outlook and Analyst Forecasts – December 7, 2025

Honeywell shares closed at $191.33 on December 5, 2025, giving the company a market cap near $121.5 billion—down about 12% from the end of 2024. Institutional investors reported mixed moves, with Jump Financial sharply increasing its stake and Gabelli Funds trimming holdings. The company is navigating a major breakup, strong aerospace demand, and weak automation business. Dividend yield stands at approximately 2.5%.
7 December 2025
·
Bengaluru’s Namma Metro in 2025: Yellow Line Boost, Pink Line Delay and Blue Line Push as Network Targets 175 km by 2027

Bengaluru’s Namma Metro in 2025: Yellow Line Boost, Pink Line Delay and Blue Line Push as Network Targets 175 km by 2027

Bengaluru’s Namma Metro crossed one million daily riders for the first time after the Yellow Line to Electronic City opened in August 2025. The network now covers 96 km and 83 stations. BMRCL plans to expand to 175 km by 2027 and 225 km by 2030, with trains every 4–6 minutes. The operator reported ₹130 crore in operational profit for FY 2023–24.
7 December 2025
Lam Research (LRCX) Stock Outlook: AI Chip Boom, Analyst Targets and 2026 Forecasts as of December 7, 2025

Lam Research (LRCX) Stock Outlook: AI Chip Boom, Analyst Targets and 2026 Forecasts as of December 7, 2025

Lam Research reported fiscal Q1 2026 revenue of $5.32 billion, up 28% year over year, with record gross margins of 50.6%. Shares closed at $158.70, up 1% Friday and about 5% below their 52-week high, giving the company a $162 billion market cap. Management guided Q2 revenue to about $5.2 billion, topping analyst estimates. Asia accounted for 87% of Q1 revenue, led by China at 43%.
7 December 2025
··
American Express (AXP) Stock on 7 December 2025: Latest News, Analyst Forecasts and 2026 Outlook

American Express (AXP) Stock on 7 December 2025: Latest News, Analyst Forecasts and 2026 Outlook

American Express closed at $370.38 on December 5, near its 52-week high of $377.23, valuing the company at about $255 billion. Q3 2025 revenue reached a record $18.4 billion, up 11% year-over-year, with EPS rising 19% to $4.14. Management raised full-year guidance, but analysts’ 12-month targets average $333, suggesting limited upside. Major institutional holders trimmed stakes but kept ownership above 84%.
7 December 2025
·
FuelCell Energy (FCEL) Stock on December 7, 2025: Rally, Hydrogen Pivot and Q4 Earnings Countdown

FuelCell Energy (FCEL) Stock on December 7, 2025: Rally, Hydrogen Pivot and Q4 Earnings Countdown

FuelCell Energy shares closed at $8.37 on December 5, up 3.85% and marking a fourth straight day of gains, though still 40% below the 52-week high. The company will report Q4 and full-year results on December 18. On December 1, FuelCell announced $25 million in new EXIM Bank financing for its Gyeonggi Green Energy project in South Korea. Trading volume Friday was 3.4 million shares, slightly below the 50-day average.
7 December 2025
···
Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals shares closed at $455.48 on December 5, 2025, valuing the company at about $115–116 billion. New data presented December 6 showed CASGEVY gene therapy achieved 12-month crisis- and transfusion-free outcomes in children 5–11 with sickle cell disease and beta thalassemia, though one pediatric patient died from transplant complications. Vertex plans global regulatory filings for this age group in early 2026.
7 December 2025
····
1 … 617 618 619 620 621 … 685
Go toTop